Search

Displaying results 3031 - 3040 of 8697 in total
  1. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  2. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … [A262556] Interaction between the notch receptors and their ligands activates proteolytic cleavage by gamma-secretase; therefore, the inhibition of gamma-secretase can potentially inhibit Notch signaling

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    Voacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries. … Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

    Categories: P-glycoprotein inhibitors
  4. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  5. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Ecallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.

  6. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.

    Categories: Detoxifying Agents for Antineoplastic Treatment
  7. Drug

    Metyrapone

    go.drugbank.com/drugs/DB01011
    ApprovedInvestigational

    An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

    Categories: Tests for Pituitary Function, Cytochrome P-450 CYP2A6 Inhibitors
  8. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [A187361] Elexacaftor, along with [VX-659], was designed to fill the need for an efficacious CF therapy for patients who are heterozygous for _F508del-CFTR_ and a gene that does not produce protein or … for the _F508del-CFTR_ gene - this represents approximately 70[A187373]-90%[A187361,A187355] of all CF patients.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Target

    Low affinity immunoglobulin gamma Fc region receptor III-B

    go.drugbank.com/bio_entities/BE0000901
    TargetHumans

    Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. … May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils

    Polypeptides: Low affinity immunoglobulin gamma Fc region receptor III-BSynonyms: IgG Fc receptor III-1